By Professor Ric Day

Journal articles

Edmonds JP; Day RO; Bertouch JV, 2002, 'The road to consensus: considerations for the safe use and prescribing of COX-2 specific inhibitors', Medical Journal of Australia, 176, pp. 332 - 334

Brooks PM; Day RO, 2001, 'OMERACT 5 Drug Safety Working Group Report: Introduction', JOURNAL OF RHEUMATOLOGY, 28, pp. 1162 - 1162, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000168487900043&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Brooks PM; Day RO, 2001, 'COX-2 inhibitors - In reply', MEDICAL JOURNAL OF AUSTRALIA, 174, pp. 368 - 369, http://dx.doi.org/10.5694/j.1326-5377.2001.tb143324.x

Lawrie MM; McKeough GN; Jones DB; Brooks PM; Day RO, 2001, 'COX-2 inhibitors (multiple letters)', Medical Journal of Australia, 174, pp. 367 - 369, http://dx.doi.org/10.5694/j.1326-5377.2001.tb143321.x

Brooks PM; Day RO, 2001, 'Drug safety module: Summary and recommendations', Journal of Rheumatology, 28, pp. 1192 - 1193

Lipani JA; Strand V; Johnson KA; Woodworth T; Furst DE; Singh G; Day RO; Brooks PM, 2001, 'OMERACT Drug Safety Working Party. A proposal for developing a large ptient population cohort for longterm safety monitoring in rheumatoid arthritis.', Journal of Rheumatology, pp. 1170 - 1173

Welch V; Singh G; Strand V; Fries JW; Boers M; Ramey D; Day RO; Brooks PM; Tugwell P; Clinch J; Kristjansson B, 2001, 'Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index', Journal of Rheumatology, pp. 1188 - 1191

Day RO, 2001, 'Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: A rheumatologists perspective', Clinical and Experimental Rheumatology, 19, pp. 59 - 62

Day RO; Mashford ML, 2001, 'Pharmacotherapeutics: what a difference five decades makes!', Medical Journal of Australia, 174, pp. 48 - 51

Woodworth T; Furst DE; Strand V; Kempeni J; Fenner H; Lau CS; Miller F; Day RO; Lipani JA; Brooks PM, 2001, 'Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group march 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies', Journal of Rheumatology, pp. 1163 - 1169

Day R, 2000, 'COX-2 Specific Inhibitors: Should I Prescribe Them?', Current Therapeutics, 41, pp. 9 - 11

Peterson G; Day R, 2000, 'COX-2 specific inhibitors and cancer (multiple letters)', Australian Journal of Hospital Pharmacy, 30, pp. 120, http://dx.doi.org/10.1002/jppr2000303120

Lipani JA; Strand V; Woodworth T; Furst DE; Singh G; Johnson KA; Day RO; Brooks PM, 2000, 'A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis', Journal of Rheumatology, pp. 827 - 830

Day RO; Morrison B; Luza A; Castaneda O; Strusberg A; Nahir M; Helgetveit KB; Kress B; Daniels BA; Bolognese J; Krupa D; Seidenberg B; Ehrich EW, 2000, 'A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis', Archives of Internal Medicine, 160, pp. 1781 - 1787

Davies NP; Mclachlan AJ; Day RO; Williams KM, 2000, 'Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor.', Clinical Pharmacokinetics, pp. 225 - 242

Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis BE; Day RO; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien T; Schnitzer TJ, 2000, 'Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis', New England Journal of Medicine, pp. 1520 - 1528

Tett S; Cutler D; Beck C; Day RO, 2000, 'Concentration effect relationship of hydroxychloroquine in patients with rheumatoid arthritis - A prospective, dose-ranging study', Journal of Rheumatology, pp. 1656 - 1660

Brooks PM; Day RO, 2000, 'COX-2 inhibitors', Medical Journal of Australia, 173, pp. 433 - 436

Day RO, 2000, 'COX-2 inhibitors: When should they be prescribed?', Current Therapeutics, pp. 9 - 11

Day RO, 2000, 'COX-2 Specific inhibitors and the hospital pharmacist', Australian Journal of Hospital Pharmacy, pp. 41 - 43

Day RO, 2000, 'COX-2 Specific inhibitors. Safer anti-inflammatory therapy?', Medicine Today, pp. 31 - 38

Day RO, 2000, 'How to make the most of a visit from a pharmaceutical company representative', Australian Prescriber, pp. 97 - 99

Day R, 2000, 'In Reply', The Australian Journal of Hospital Pharmacy, 30, pp. 120 - 120, http://dx.doi.org/10.1002/jppr2000303120a

O Sullivan AJ; Kennedy M; Day RO; Case J; Corrigan B; Wodak AD, 2000, 'Medical assessment of anabolic-androgenic steroid users', Medical Journal of Australia, 173, pp. 323 - 327

Welch SA; Novy M; Preiz P; Quinn DI; Whicker SD; Brown S; Day RO, 2000, 'Promoting rational prescribing by emergency department junior medical officers', Australian Journal of Hospital Pharmacy, pp. 262 - 270

Day RO; Graham GG; Whelton A, 2000, 'The position of paracetamol in the world of analgesics', American Journal of Therapeutics, pp. 51 - 54

Day RO; Graham GG; Whelton A, 2000, 'The position of paracetamol in the world of analgesics.', American Journal of Therapeutics, pp. 51 - 54

Williams KM; Day RO; Roberts LK; Harbin JA, 1999, 'A comparison of the efficacy of α-ketobutyric acid (KBA), nordihidro-guaiaretic acid (NDGA), salicylic acid (SA), and placebo (P) in the accelerated removal of corns', Clinical Pharmacology and Therapeutics, 65, pp. 122, http://dx.doi.org/10.1016/S0009-9236(99)80022-8

Day RO; Brooks PM; Petersen M; Conaghan P, 1999, 'Efficacy and safety of intraarticular hyaluronic acid in osteoarthritis', Clinical Pharmacology and Therapeutics, 65, pp. 172, http://dx.doi.org/10.1016/S0009-9236(99)80220-3

Brooks P; Emery P; Evans JF; Fenner H; Hawkey CJ; Patrono C; Smolen J; Breedveld F; Day R; Dougados M; Ehrich EW; Gijon-Baños J; Kvien TK; Van Rijswijk MH; Warner T; Zeidler H, 1999, 'The International Consensus Meeting on the Mode of Action of COX-2 Inhibition, 5-6 December 1997: Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2', Rheumatology, 38, pp. 779 - 788, http://dx.doi.org/10.1093/rheumatology/38.8.779

Graham GG; Day RO; Milligan MK; Ziegler JB; Kettle AJ, 1999, 'Current Concepts of the actions of paracetamol (acetaminophen) and NSAIDS', Inflammopharmacology, pp. 255 - 263

Brooks PM; Emery P; Evans JF; Fenner H; Hawkey CJ; Patrono C; Smolen J; Breedveld F; Day RO; Dougados M; Ehrich EW; Gijon-Banos J; Kvien T; Van Rijswijk MH; Warner T; Zeidler H, 1999, 'Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2', Rheumatology, pp. 779 - 788

Ray JE; Marriott D; Day RO, 1999, 'MANAGING ANTI-TUBERCULOSIS DRUG THERAPY BY THERAPEUTIC DRUG MONITORING OF ISONIAZID AND RIFAMPICIN.', Therapeutic Drug Monitoring, 21, pp. 456 - 456, http://dx.doi.org/10.1097/00007691-199908000-00119

Gazarian M; Tugwell P; Boers M; Bombardier C; Brooks PM; Day RO; Strand V; Wells G, 1999, 'Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress for the OMERACT drug toxicity working party', Journal of Rheumatology, pp. 207 - 209

Gazarian M; Tugwell P; Boers M; Bombardier C; Brooks PM; Day RO; Strand V; Wells G, 1999, 'Patient based methods for assessing adverse events in clinical trials in Rheumatology. Progress report for the Omeract Drug Toxicity Working Party', Journal of Rheumatology, pp. 207 - 209

Day RO; Mclachlan AJ; Graham GG; Williams KM, 1999, 'Pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid', Clinical Pharmacokinetics, pp. 191 - 210

Browne GS; Nelson CJ; Nguyen TM; Ellis B; Day RO; Williams KM, 1999, 'Stereoselective and substrate-dependent inhibition of hepatic mitochondrial B-oxidation and oxidative phosphorylation by the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen and ketorolac', Biochemical Pharmacology, pp. 837 - 844

Erb K; Brugger R; Williams KM; Geisslinger G, 1999, 'Stereoselective disposition of tiaprofenic acid enantiomers in rats', Chirality, 11, pp. 103 - 108

Day RO; Rowett D; Roughead EE, 1999, 'Towards the safer use of non-steroidal anti-inflammatory drugs', Journal of Quality in Clinical Practice, 19, pp. 51 - 53

Carmody JJ; Walker JS; Sheather-Reid RB; Vial JH; Day RO, 1998, 'Non-steroidal anti-inflammatory drugs (NSAIDs): Support for the concept of 'responders' and 'non-responders', NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 358, pp. R450 - R450, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000075207800302&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Quinn DI; Day RO, 1998, 'A GP`s guide to clinically important drug interactions', Modern Medicine of Australia, pp. 89 - 103

Quinn DI; Markus R; Day RO, 1998, 'Antiepileptic therapy', Current Therapeutics, pp. 23 - 37

Quinn DI; Day RO, 1998, 'Drug Interactions Alert', First Ed., pp. 38

Scheuerer S; Williams KM; Brugger R; Mclachlan AJ; Brune K; Day RO; Geisslinger G, 1998, 'Effect of clofibrate on the chiral inversion of ibuprofen in rats', Journal of Pharmacology and Experimental Therapeutics, pp. 1132 - 1138

Weekes LM; Brooks C; Day RO, 1998, 'Indicators for Drug and Therapeutics Committees', British Journal of Clinical Pharmacology, pp. 393 - 398

Weekes LM; Brooks C; Day RO, 1998, 'Indicators for Drug and Therapeutics Committees', British Journal of Clinical Pharmacology, 45, pp. 393 - 398, http://dx.doi.org/10.1046/j.1365-2125.1998.00699.x

Bramley-Moore S; Wodak AD; Day RO; Lauchlan RL, 1998, 'Patterns of analgesic prescribing for patients with chronic non-malignant pain in NSW', Australian Journal of Hospital Pharmacy, pp. 83 - 88

Bramley-Moore S; Wodak AD; Day RO; Lauchlan RL, 1998, 'Patterns of analgesic prescribing patients with chronic non-malignant pain in NSW', Australian Journal of Hospital Pharmacy, pp. 83 - 88

Brooks PM, 1998, 'Pharmaceutical company promotion: striking a balance', Australian and New Zealand Journal of Medicine, pp. 291 - 293

Weekes LM; Day RO, 1998, 'The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees: an Australian perspective.', Drug Safety, 18, pp. 153 - 159

Back to profile page